Investors Inquire about Jinjia's Plan for Domestic E-cigarette Sales

Business by 2FIRSTS.ai

May.15.2024

Investors Inquire about Jinjia's Plan for Domestic E-cigarette Sales

Investors inquire about Jinjia (002191) applying to sell its own e-cigarette brand domestically this year, company plans overseas sales.

Recently, investors inquired on the investor interaction platform about whether Jinjia Group (002191) has plans to reapply for domestic sales of its own e-cigarette brand this year.

In response, Jingjia Corporation stated that, based on the relevant e-cigarette regulations in China and considering market conditions, the company's own brand of e-cigarette products are not sold domestically and are primarily marketed towards overseas regions.

References:

[1] 问答详情

Also Read:

[1] Jinjia Corporation Cancels Plan to Invest in UK

[2] Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director

[3] Jinjia Group Appoints Interim Chairman and Legal Representative

[4] Jinjia Group: Continued Investment in E-Cigarettes

[5] Jinjia Group to Invest £500,000 ($634,000) for Establishment of Subsidiary in London

[6] Jinjia Holdings Expands Comprehensive Layout in New Tobacco Industry

#Asia #Open system e-cigarettes #China #Regulation #jinjia

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria and NJOY Sue ITC, Claim Judge Appointment Process Is Unconstitutional

Altria Group and its NJOY subsidiary have filed a lawsuit in Virginia federal court challenging the U.S. International Trade Commission’s process for appointing administrative law judges. The companies allege the system violates the U.S. Constitution and seek to halt an ITC patent investigation initiated by rival Juul.

Nov.10

Products | VAPORESSO Unveils Two New 10 mL Pod Devices for UK and US E-Commerce Channels

VAPORESSO has recently launched two new open-system vaping devices. The XROS 5 Nano is the first to roll out across UK and US online channels, featuring 30W output and a touch-screen design, while the ECO NANO Plus has gone live on the brand’s official website with a 10 mL high-capacity pod and a 1400 mAh battery.

Nov.26 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million

British American Tobacco (BAT) acquires state-owned shares of UZBAT, a joint venture in Uzbekistan, for $22.3 million.